ATAI News and Press, ATAI Life Sciences N.V. From 01/17/23

--News Direct-- When psychedelics were first studied more than 50 years ago, researchers discovered that they were useful in assisting people in exploring a greater sense of self. After a half-century hiatus, scientists are once again investigating psychedelics and other mind-altering substan...

Summary Stephen Tobin on investing in psychedelic stocks while they're still pre-revenue. Will first-movers get the advantage? Importance of patents and cash in the industry. Why he's a big believer in Compass and Atai and not as much in Cybin or MindMed. What will move share pr...

Various indigenous cultures found, used, and promoted plant-based psychedelics for human wellness and spiritual development for thousands of years, in almost every place where humans lived on the planet. Psilocybin is a sacred herb grown and consumed in many places around the world, including...

New research has found that the intensity of a psilocybin trip doesn’t depend on an individual’s body mass index (BMI). BMI is a measure of body fat based on height and weight that applies to adults. Psilocybin is the primary psychoactive compound found in hallucinogenic mushroo...

GRX-917 (deuterated etifoxine) was well-tolerated with no dose-limiting toxicities and only mild adverse effects comparable to that of placebo in both single and multiple ascending doses, as previously announced as preliminary results during atai’s R&D day. Final results demonstrat...

Summary What makes a psychedelic company compelling? Analyst Alex Carchidi has a background in biotech and focuses on long-term growth and risk management. He shares what investors should focus on in the sector and the pros and cons of owning his top 5 psychedelic stocks. ...

Shares of Atai Life Sciences (Nasdaq: ATAI) plunged by more than 40% after phase 2a clinical trial results looking at ketamine therapy to treat depression failed to meet its primary endpoint. Atai said that while findings showed “signals of efficacy across all timepoints out to two...

Atai Life Sciences ( NASDAQ: ATAI ) said its majority-owned unit Perception Neuroscience's therapy PCN-101 (R-ketamine)  did not meet the main goal of a phase 2a trial for treatment-resistant depression. The study evaluated efficacy of a single IV administration of PCN-1...

NEW YORK and BERLIN, Jan. 06, 2023 (GLOBE NEWSWIRE) -- atai Life Sciences (NASDAQ: ATAI) (“atai” or “the Company”), a clinical-stage biopharmaceutical company focused on mental health, announced that, while PCN-101 (R-ketamine) demonstrated signals of efficacy across a...

Every few years, new or previously forgotten discoveries shake up the very foundation of how industries operate. The development of the internet, for instance, altered society in a multitude of ways, enabling previously unknown ways of connecting and thinking and completely revolutionizing how ...